Skip to content
    HighLight Capital logo

    HighLight Capital

    Shanghai, ChinaFounded 2014
    www.hlcfund.comLinkedIn
    HealthcareBiotech & Life Sciences

    HighLight Capital (HLC) is a healthcare-focused venture capital firm founded in 2014 and headquartered in Shanghai, China, with offices in Tokyo, Hong Kong, and Boston. The firm invests in biotech, medtech, and healthcare services across early and growth stages. HLC's latest vehicle, HLC USD Fund IV, closed at approximately $550 million in December 2023; across all vehicles the firm manages over US$3.8 billion in total AUM.

    35% of their portfolio is in Biotech & Life Sciences. Deal activity increased 250% year-over-year (7 deals in the last 12 months). Their most common stage is series-b (46% of deals). Average disclosed round size is $114.2M (across 27 rounds with reported amounts).

    Find people at HighLight Capital on Goldilocks AI

    Portfolio

    29

    Fund Size

    $550M

    Top Stage

    Series B

    Last 12 Mo

    7

    Team

    LE

    Laura Erakovic

    Founding Managing Partner

    SS

    Shuichi Shimizu

    Managing Director

    BX

    Bruce X.

    Venture Partner

    XH

    Xing He

    Partner

    AG

    Allen Greenstein

    Director

    DX

    Di Xue

    Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    37 investments
    CompanyRoundAmountDate
    Aureka Biotechnologies logoAureka BiotechnologiesSeries B$100MAug 2026
    AAurekaSeries B$100MAug 2026
    Lysoway Therapeutics logoLysoway TherapeuticsSeries A$22MJun 2026
    VVivaTides TherapeuticsSeries A$54MApr 2026
    QQujing TechnologySeries A—Jan 2026
    AAurekaSeries B$100MJan 2026
    Aureka Biotechnologies logoAureka BiotechnologiesSeries B$100MJan 2026
    T-CURX logoT-CURXSeries A—Dec 2025
    Allegria Therapeutics logoAllegria TherapeuticsSeed$5.1MDec 2025
    Arthrosi Therapeutics logoArthrosi TherapeuticsSeries E$153MOct 2025
    VelaVigo logoVelaVigoSeed$60MJul 2025
    Nuevocor logoNuevocorSeries B$45MMay 2025
    NUCLIDIUM AG logoNUCLIDIUM AGSeries B—Jan 2025
    IInfinigence AISeries A—Jan 2025
    Nuevocor logoNuevocorSeries B$45MJan 2025
    T-CURX logoT-CURXSeries A$20MJan 2025
    IImagoSeries B$1.4MJan 2025
    MMediLinkSeries B$70MApr 2022
    MMediLink TherapeuticsSeries B$70MApr 2022
    MMediLink TherapeuticsSeries B$70MMar 2022
    ABM Therapeutics logoABM TherapeuticsSeries B$30MJan 2022
    Bristar Immunotech logoBristar ImmunotechSeries C—Oct 2021
    AAbogenSeries C$700MAug 2021
    AAbogen BiosciencesSeries C$700MAug 2021
    IInmageneSeries C$100MJun 2021
    Page 1 of 2

    Top Co-Investors

    Loyal Valley Capital6 shared
    Legend Capital6 shared
    LYFE Capital5 shared
    Granite Asia4 shared
    Bayern Kapital3 shared
    Angelini Ventures3 shared
    Kurma Partners3 shared
    K2VC3 shared
    MRL Ventures Fund3 shared
    Greenspring Associates3 shared
    Omega Funds3 shared
    Frazier Healthcare Partners3 shared
    Amgen Ventures3 shared
    LinkX Capital3 shared
    LAV3 shared
    Apricot Capital2 shared
    Panacea Venture2 shared
    Legend Star2 shared
    GG12 shared
    BlackRock Private Equity Partners2 shared

    Last updated: 7 October 2026